Transcriptome And Lipidome Profile Of Human Mesenchymal Stem Cells With Reduced Senescence And Increased Trilineage Differentiation Ability Upon Drug Treatment
Jul 11, 2022
Please contact oscar.xiao@wecistanche.com for more information
ABSTRACT
Human Mesenchymal stem cells(hMSCs) are multi-potential cells that are widely used in cell therapy. However, the frequently emerged senescence and decrease of differentiation capabilities limited the broad applications of MSC. Several strategies such as small molecule treatment have been widely studied and used to improve the stem characteristics by bypassing senescence but the exact mechanisms for them to reduce senescence have not been fully studied. In this study, hMSCs were treated with rapamycin, oltipraz, metformin, and vitamin C for the indicated time and these cells were subjected to senescence evaluation and trilineage differentiation. Furthermore, transcriptomics and lipidomics datasets of hMSCs after drug treatment were analyzed to interpret biological pathways responsible for their anti-senescence effects. Although four drugs exhibited significant activities in promoting MSC osteogenic differentiation, metformin is the optimal drug to promote trilineage differentiation. GO terms illustrated that the anti-aging effects of drugs were mainly associated with cellular senescence, mitotic, and meiosis processes. Biosynthesis of phosphatidylcholines (PC) and phosphatidylethanolamine (PE) were inhibited whereas the production of phosphatidylinositols(PIs) and saturated fatty acids (SFA)/ mono-unsaturated fatty acids(MUFA)conversion was activated. Medium-free fatty acids (FFA) were increased in hMSCs with different anti-aging phenotypes. Therefore, we established a comprehensive method for assessing drug intervention based on the results of transcriptomics and lipidomics. The method can be used to study different biological phenotypes upon drug intervention in MSC which will extend the clinical application of hMSCs.

Please click here to know more
INTRODUCTION
Aging, a time-dependent process, will cause physiological dysfunction. Aging is the primary risk factor for many diseases, including cancer, neurodegenerative diseases, and diabetes. Stem cell exhaustion and cellular senescence are one of the hallmarks that determine physiological phenotype during aging [1]. Human mesenchymal stem cells (hMSCs) are multi-potential cells presented in bone marrow, adipose tissue, placenta, umbilical cord, muscle, and many other tissues [2-6]. Under lineage-specific medium, hMSCs can undergo differentiation into adipocyte, osteoblast, and chondrocytes as well as other cell lineages in vitro. Therefore, hMSCs play important roles in regenerative medicine and cell therapy. However, the clinical usage of MSC is limited by the aging during the longer culture in vitro. hMSCs aging was usually associated with the change of telomere length, cell density, proliferation potential, tilineage differentiation potential, epigenetics, mitochondrial function, and secretome [7]. Therefore, overcoming MSC aging warrants more in-depth studies to explore the strategies to inhibit hMSC senescence. Metformin (TAME) is the first drug that was approved in a clinical trial to delay aging [8] and is also an FDA-approved first-line drug for treating type e 2 diabetes mellitus [9]. cistanch The agonizing Nrf2 pathway is thought the underlying mechanism for metformin to mediate lifespan elongation [10]. Oltipraz, an antischistosomal agent, was also used to inhibit cancer progression via the NRF2 pathway in a rodent model[11, 12]. It was also reported that oltipraz exhibited an anti-aging effect by repressing the antioxidant NRF2 pathway [13]. Moreover, rapamycin (Sirolimus) was used to coat coronary stents, prevent organ transplant rejection and treat lymphangioleiomyomatosis [14]. It was reported that rapamycin could inhibit the activation of T cells and B cells through mTOR inhibition [15], which has been further confirmed by the aggravation of the deficiency of stem cells [16]. Vitamin C is a well-known reductant and has been reported to alleviate aging in the Werner syndrome stem cell model[17]. However, whether they shared similar pathways to exert their roles in anti-aging and the specific mechanisms for suppressing cellular aging in humans remains unclear. Furthermore, the transcriptome and lipidome for these MSC treated by the four drugs were not fully investigated which urged us to perform the below experiments to address these important questions.

Cistanche can anti-aging
In this study, metformin, oltipraz, rapamycin, and vitamin C were used to treat Bone Marrow hMSCs (BM-hMSCs). Firstly, differentiation phenotypes of hMSCs after treatment were characterized to illustrate their anti-aging potentials. Transcriptomics and lipidomics analysis was performed on the drug-treated cells. Afterward, GO analysis based on the transcriptomics dataset was carried out to anchor the signaling events responsible for senescence and anti-aging activities. Metabolic profiling and pathway analysis were conducted which illustrates a fluctuation of lipids production during drug treatment. Altogether, we have established an overall evaluation system of drug intervention on hMSCs senescence. The system can be used to study different biological phenotypes upon drug intervention in MSC which will extend the clinical application of hMSCs.
RESULTS
BM-hMSC subjects to senescence after a long time of culture in vitro
BM-hMSCs are multipotent stem cells with common characteristics of self-renew and differentiation into different cell types. However, with the passage increasing in vitro, cells are gradually subject to senescence and will lose the majority of their differentiation capabilities. The status of BM-hMSCs was analyzed at different passages (P2, P8, P13)and the cell's condition became worse, proved by the slowing down of cell proliferation, the increase of death, and the lengthening of morphology(Figure 1A). Furthermore, the trilineage differentiation abilities of P8 BM-hMSCs were also tested. As shown in Figure 1B, compared with that from our previous studies [18], the differentiation abilities of P8 BM-has decreased, but can still differentiate to osteoblasts, adipocytes, and chondrocytes under induction medium. cistanche Australia According to the in vitro MSC senescence model as reported [18], we further treated BM-hMSCs with four candidate drugs aiming to intervene in the senescence in vitro. As shown in Figure iC, cells were plated in a 24-well plate with a density of 60 percent, and drugs were added to the cells after 48 hours. The supernatant of cells was collected every three days seven times. On day 21 after the drug

(Supplementary Figure 1A). Oltipraz, rapamycin, and vitamin C can effectively improve the differentiation potential which was directly proportional to the antagonism of senescence (Supplementary Figure 1B). Interestingly, only oltipraz showed a positive effect on adipocytes differentiation medium (Supplementary Figure 1C,1D). cistanche benefits, In summary, oltipraz is the best drug for improving trilineage differentiation abilities, rapamycin and vitamin C could effectively improve osteogenic and chondrogenic differentiation potential, while metformin only exhibits a limited positive effect on osteogenic differentiation.

Transcriptomics profile of drug-treated BM-hMSCs Given that all four drugs could counteract the senescence of BM-hMSCs with diverse efficiency, next we sought to explore the underlying mechanisms for their distinct effect by investigating the transcriptomic profile of BM-hMSCs upon drug treatment. We calculated the fold-change of gene expression between each drug-control pair respectively. For each drug-control pair, the differentially expressed genes (DEGs) with fold-change above 2 were selected, which contain both upregulating and downregulating genes(Supplementary Table 1). We got 1758 genes in total after analyzing all the DEGs from the drugs treated BM-hMSCs (Figure 3A). To investigate the functions of the DEGs, we identify the enriched gene ontology(GO) terms("p<0.01) based on each drug's DEGs [19](Supplementary Table 2). These enriched GO terms represent the functions influenced by the drugs. Furthermore, we plot the Venn diagram to study the similarity and specificity of the enriched GO terms. As shown in Figure 3B, although each drug has its unique regulated GO terms, the drugs also share a common GO which suggests that there are common functions influenced by all four drugs. These common GO terms may associate with the effects of the drug on senescence alleviation and trilineage differentiation improvement.
Twelve common GO terms were shared by four drugs (Figure 3B,3D), of which mainly enriched in the negative regulation of cell motility (Figure 3E), positive regulation of actomyosin structure organization, regulation of cellular process and cellular component organization, cytoskeleton organization, macromolecule catabolic process, regulation of cell proliferation, protein catabolic process and small GTPase mediated signal transduction(Figure 3C, 3E). These functions are closely related to cell fate, especially senescence-related phenotypes.
After analyzing the common GO terms between metformin and oltipraz, we found that they share the same function as the NRF2 agonists. As shown in Figure 3F, the function of the cell cycle, macromolecule catabolic process, and nuclear envelope organization were upregulated. Moreover, the function for component movement, cell migration/adhesion, and response to vitamin E/organic cyclic compound/lipid was downregulated (Figure 3G). These results altogether indicated that metformin and oltipraz may affect cell differentiation abilities, cell fate, and cell metabolism. As oltipraz is the best drug to improve trilineage differentiation abilities, we further sought to identify the specific pathways altered by oltipraz. Interestingly, the enriched 85 GO terms were mainly related to cellular senescence, cell cycle, mitotic and meiosis process, cellular response to drugs, vitamin, cAMP, DNA damage stimulus, nutrient and osmotic stress (Supplementary Figure 2A,2B). Lipidomics profile of drug-treated BM-hMSCs To investigate the global fluctuation of lipids regarding BM-hMSCs osteogenic differentiation upon drug treatment, the LC-MS-based lipidomics profiling analysis was conducted.A total of 139 lipid species were identified in cellular lipidome, including lysophosphatidylethanolamines(LPE),21 PEs, 4 PE-Os, 4 phosphatidylinositols(PI),5 phosphatidylserines(PS), 8 Ceramides(Cer),4 Cerys, 11 sphingomyelins(SM),6 diacylglycerides(DG),18 triacylglycerides (TG) and 20 free fatty acids(FFA)(Figure 4A-4M). According to the clustering matter, cells treated with oltipraz showed the largest variations of lipids, which was in agreement with its best effect on cell senescence alleviation and trilineage differentiation improvement. In detail, monophosphatidylglycerols LPCs were increased in the oltipraz treatment group compared with the control, whereas their counterparts PCs and PEs were down-regulated (Figure 4B,4D,4E). The levels of PIs and SFAs are also elevated while the level of Ceres and MUFAs were reduced (Figure 4F, 4L,4H,4M). These results
Lipidomics- and transcriptomics-based pathway analysis in drug-treated hMSCs
To further investigate the underlying mechanisms for the improvement of trilineage differentiation by oltipraz, pathway analysis was performed based on the lipidomic and transcriptomic datasets. As shown in Figure 5A, CDP-Diacylglycerol Synthase 1(CDS1)was the only enzyme up-regulated in oltipraz treated cells, which might be the reason to cause elevation of PIs and reductions of PCs. However, the down-regulated lecithin cholesterol acyl transferase (LCAT) and unchanged lysophosphatidylcholine acyltransferase3 (LPCAT3) were inconsistent with the increased LPCs, suggesting the excessively produced LPCs may not be synthesized from PCs/Pes(Figure 5A). Interestingly, an obvious conversion could be observed between SFAs and MUFAs(Figure 5B). The increase in saturated fatty acids(SFA)and decrease in MUFAs may result from the down-regulated stearoyl-CoA desaturase (SCD). This layout tends to reveal the mechanism for the decreased activity of lipogenesis after treatment with oltipraz. Although oltipraz treatment could reduce the production of Ceres, the conversions mediated by Cars were not significantly altered (Figure 5C).
Global profiles of lipid species in hMSCs supernatant upon drug treatment
Furthermore, the lipidomics alterations in the medium were characterized in order to thoroughly investigate the influence of drugs on hMSCs. As shown in Supplementary Table 3, clustering analysis demonstrated that the lipids were classified into two clusters, ie. the majority of FFAs and other lipids(non-FFAs). cistanche cholesterol As shown in Figure 6, in four groups, FFAs exhibited obvious alterations at different treatment periods. In contrast, non-FFAs showed slight fluctuations in four groups (Figure 6A-6D). The FFAs were significantly elevated at early stages in all groups (Figure 6E-6H). cistanche deserticola side effects Moreover, FFAs in cells induced by metformin (Figure 6E), oltipraz, and vitamin C treatment rapidly increased from the 2nd time point to the 3rd time point. However, in the cells treated with rapamycin, FFAs were elevated from the list to the 2nd time point (Figure 6F-6H). Interestingly, FFAs in metformin-treated cells showed a greater decline than in the other three groups (Figure 6E). Then, slight rises of FFAs could be seen in the oltipraz and vitamin C treatment group while from the 4th to the 5th time point, FFAs showed a slight decline in the metformin treatment group (Figure 6E, 6F, 6H).

In rapamycin-treated cells, levels of FFAs were basically maintained from the 3rd to the 5th time point. Specifically, as shown in Supplementary Figure 3 and Supplementary Table 4, the alteration patterns of FFAs could be further classified into 8 clusters. Therein, cluster 6 mainly consisting of SFAs showed the same layout as those shown in the oltipraz and vitamin C group, while cluster I was basically the same as the rapamycin group. Generally, the medium-FFAs in all groups except for metformin were globally increased along with the inducement, suggesting the association between FFAs in the internal cultural environment and cell senescence. Cells induced by metformin and vitamin C contributed a similar influence to the SFAs in the internal environment compared with rapamycin induction (Figure 6A,6D,6E,6H).
The general strategy to study the anti-aging effects of drugs in hMSCs
To sum up, as shown in Figure 7, to characterize the anti-aging effects of four drugs in hMSCs, a systematic study was conducted based on the workshop consisting of phenotype characterization, transcriptomics, cell lipidomics, and medium lipidomics analysis. Oltipraz alleviated senescence and improved trilineage differentiation efficiency by promoting the production of PIs, inhibiting the biosynthesis of PCs/PEs, and blocking the conversion from SFA to MUFA. GO terms also illustrated the phenotype associated with cellular senescence, mitotic and meiosis process, cellular response to DNA damage stimulus, ammonium ion, and oxygen levels. Interestingly, the NRF2 pathway was regulated by both oltipraz and metformin to promote cell differentiation to different degrees. Meanwhile, the medium lipidomics layout demonstrated the critical roles of medium FFAs in MSC differentiation into multiple cell types. Therefore, the multidimensional strategy provides multiple perspectives to interpret different effects of drug intervention on hMSCs senescence. This method can be used to study different biological phenotypes upon drug intervention in MSC which will extend the clinical application of hMSCs.

DISCUSSION
The novel coronavirus disease 2019(COVID-19)has grown to be a global public health emergency. Currently, there were no specific drugs to protect the patients from immunomodulatory effects. It was reported that the application of MSC in COVID-19 severe cases improves the outcome of the patients by regulating the inflammatory response of the body and promoting lung tissue repair and regeneration [20]. However, frequently emerging senescence of hMSCs during longer time culture in vitro hampered the clinical application of hMSCs. In this study, we establish an in vitro drug screening system based on the BM-hMSCs senescence phenotype [21]. Many studies conducted aging-related intervention research for hMSCs based on manipulation of TFs [22-27] and application of different drugs [10. 13,17,28,29].However, we are the first to thoroughly assess the anti-aging effect of different drugs on BM-hMSCs from the perspective of SA-β-gal activity and differentiation efficiency. Rapamycin, oltipraz, metformin, and vitamin C are the four traditional drugs firstly used for hMSCs aging intervention. Although all the four drugs counteract BM-MSC senescence, the exact effects and underlying mechanism of the four drugs in promoting cell differentiation were different. More importantly, we also establish an overall evaluation system of drug intervention by integrated analysis of transcriptomics and lipidomics profiles in cell supernatants and lysates. In detail, transcriptomics data were fully analyzed in combination with the phenotype of stem cells after drug treatment to explore the altered pathway and underlying mechanisms influenced by drug treatment. Moreover, the lipid change pattern of cells treated with different drugs at different time points was determined by LC-MS. Furthermore, through integrating the data of transcriptomics and lipid metabonomic, drug-specific metabolic pathways and drug-related lipid changes were analyzed and summarized.

Oltipraz is the best drug to improve the differentiation abilities of BM-hMSCs among four drugs. The DEGs affected by oltipraz treatment were mainly enriched in cellular senescence, cell cycle, and cellular response to drugs, cAMP, and so on. These changes play critical roles in cellular aging However, oltipraz and metformin, the Nrf2 pathway inhibitors, influenced common regulatory pathways [30], which mainly enriched cell differentiation abilities, cell fate, and cell metabolism. As an inhibitor of the mTOR pathway, rapamycin could prevent cellular senescence [31, 32]Consistently, we also found that rapamycin plays the best role in promoting the osteogenic differentiation which mainly through regulating phosphate-containing compound metabolic process pathway, cellular component organization, cell communication, signal transduction, macromolecule biosynthetic process, cellular protein metabolic process, and skeletal system development. Vitamin C is a well-known reductant and it plays the best role in promoting cell proliferation compared with the other three drugs, but there was no significant effect in the trilineage differentiation abilities improvement of MSC. These phenotypes may be caused by the response to cytokine/lipid/oxidative stress, and positive regulation of catalytic activity (Supplementary Figure 4).
Lipids have been demonstrated to play irreplaceable roles in the differentiation of stem cells [33]. We previously found that the increases of membrane glycerophospholipids including PCs and PEs, a hallmark of senescence, were globally observed in the aged MSCs[18]. In the current study, the reductions in PCs and PEs were observed in the cells treated with oltipraz which performed best in delaying senescence of MSCs PCs and PEs are the lipids with the highest abundances in the construction of eukaryotic membranes 34]. The increased levels of PCs and PEs in sera have been shown in elder people compared with younger individuals [34]. Interestingly, PIs were the minority GPLs decreased in aged MSCs in our previous observations. In this study, PIs were dramatically elevated in all induced cells. Mechanically, pathway analysis suggested that the increases in PIs may be associated with the activated CDS1.CDS1 kinase has been proved to participate in the regulation of ROS signaling and further influence the expression of genes that functioned in oxidative resistance [35]. Another significantly blocked metabolic flux is the conversion from SFA to MUFA mediated by SCD. As a biobarometer of lipogenesis, the activated SFA/MUFA has been observed in a batch of diseases such as cancer and nonalcoholic fatty liver disease(NAFLD)[36,37] Similar results are also observed in aged mice, which reflects the abnormal metabolism of lipids in the liver during aging [38]. Altogether, our strategy can be used in anti-aging drug screening and molecular mechanism exploration after drug treatment in stem cells and cancer. By combining the strategy with the evaluation system, we can perform real-time monitoring based on the aging-related status of stem cells to discover new drugs which will be used in stem cell therapies.
This article is extracted from www.aging-us.com






